E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114
There is an ongoing need for first-line (1L) chemotherapies for metastatic HER2-negative breast cancer. This study evaluated the efficacy and safety profile of the dose-expansion part 6 of Study 114 in patients receiving E7389-LF as a 1L chemotherapy for metastatic/advanced HER2-negative breast cancer. Japanese patient...